Neuren has placed itself in a slightly vulnerable position with regards its future.
The company has less than 2 dozen employees which confirms that it is in no position to take NNZ-2591 to the market (subject to approval) in a timely manner.
There only appears two options - a takeover or licensing deal.
JP has been quite emphatic (in the past) on not preferring the licensing model.
Surely any potential acquirer would be noting that, despite the huge potential of NNZ-2591, the company is not in the most powerful position to control its ultimate destiny.
I'm not sure what Neuren can do to pull itself out of this predicament other than knock the socks off the phase 3 trial, and even that doesn't really change the fact that they are not positioned in any fashion to go it alone.
NEU Price at posting:
$10.81 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)